ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Published Study Validates Agendiaโs MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Low Recurrence Risk up to 25 Years after Diagnosis, Further Validating NEJM Study IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 17,2014 โ A newly published Read More
Agendiaโs MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference
Next-Generation Genomic Tests Determine Molecular Subtypes and Risk of Recurrence, Providing More Precise Prognosis and Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS, January 30, 2014 โ Molecular subtyping provides a more precise prognosis and valuable Read More
Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDsโ Attention on Second-Generation Symphony Suite for Recurrence Risk and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 23, 2013 โ Agendiaโs innovations in genomic testing Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 โ New breast cancer research incorporating ย the SymphonyTM suite Read More